Search - tctmd.com

Displaying 361 - 380 of 462

Sort: Relevancy | Date

Presentation

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Presenter: Martin T. Rothman

December 01, 2013

News Conference News TCT 2013

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

November 04, 2013

Presentation TCT 2013

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Presenter: Jean-Philippe Collet

October 31, 2013

Presentation TCT 2013

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Presenter: Fausto Feres

October 31, 2013

Presentation TCT 2013

Dual Anti-Platelet Therapy Plus Warfarin: WOEST Recap, and Recommendations for Adoption

Presenter: Freek Verheugt

October 31, 2013

Presentation TCT 2013

Dual Anti-Platelet Therapy Plus the New Chronic Oral Anticoagulants: What Do We Know?

Presenter: Pascal Vranckx

October 31, 2013

Presentation TCT 2013

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

Presenter: Matthew Price

October 30, 2013

Presentation TCT 2013

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

Presenter: Byoung Kwon Lee

October 29, 2013

Presentation TCT 2013

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Presenter: Laura Mauri

October 29, 2013

News Daily News

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Caitlin E. Cox

October 23, 2013

News Daily News

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

Jason Kahn

October 11, 2013

News Daily News

La Aspirina a Largo Plazo es tan Eficaz como la Terapia Doble en Pacientes SLF Sin Complicaciones

Jason Kahn

October 11, 2013

Presentation

Optimal Duration Of Dual Antiplatelet Therapy After DES Implantation

Presenter: C.W. Lee

October 10, 2013

News Daily News

Failure to Give Pre-PCI Aspirin Not Infrequent Cause of Complications

Caitlin E. Cox

October 04, 2013

Presentation ESC 2013

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Presenter: 32040|Roxana Mehran

September 01, 2013

News Conference News ESC 2013

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

Yael L. Maxwell

September 01, 2013

News Daily News

El Riesgo Hemorrágico de la Terapia Triple No lo Atenúa la Warfarina Bien Controlada

August 30, 2013

News Daily News

Bleeding Risk of Triple Therapy Not Attenuated by Well-Controlled Warfarin

August 30, 2013

News Daily News

In Older ACS Patients, Half-Dose Prasugrel as Safe as Clopidogrel But No More Effective

July 25, 2013

News Daily News

En Pacientes Ancianos, Media Dosis de Prasugrel es igual de Segura que el Clopidogrel aunque No Más Eficaz

July 25, 2013

Advertisement

Clinical outcomes associated with dual antiplatelet therapy interruption following implantation of the ResoluteTM zotarolimus-eluting stent

Triple Antiplatelet Therapy with Cilostazol Increases Tachycardia, Arrhythmias

ARCTIC-INTERRUPTION: A Prospective, Randomized Trial of Two Years vs. One Year of Dual Antiplatelet Therapy After PCI

Featured Trial of the Day: OPTIMIZE: A Prospective, Randomized Trial of Three Months vs. 12 Months of Dual Antiplatelet Therapy After PCI

Dual Anti-Platelet Therapy Plus Warfarin: WOEST Recap, and Recommendations for Adoption

Dual Anti-Platelet Therapy Plus the New Chronic Oral Anticoagulants: What Do We Know?

Antiplatelet Agent Conundrums: Potency, Resistance, Duration, and Single/Dual/Triple Therapy

TCT-8. 6-month versus 12-month dual antiplatelet therapy after implantation of 2nd generation drug-eluting stents with Biolimus-eluting Versus Zotarolimus-eluting stent:...

TCT-10. Differences Between US and non-US Cohorts after PCI and Dual Antiplatelet Therapy: Patient Characteristics, Randomization

Longer DAPT Duration Reduces Adverse Events After PCI for In-Stent Restenosis

Long-term Aspirin as Effective as Dual Therapy in Uncomplicated DES Patients

La Aspirina a Largo Plazo es tan Eficaz como la Terapia Doble en Pacientes SLF Sin Complicaciones

Optimal Duration Of Dual Antiplatelet Therapy After DES Implantation

Failure to Give Pre-PCI Aspirin Not Infrequent Cause of Complications

Incidence and Impact of Dual Antiplatelet Therapy (DAPT) Cessation on Adverse Events following Percutaneous Coronary Intervention (PCI):Results from the Real-World PARIS Registry

Length of DAPT, Reasons for Discontinuation Have Disparate Effects

El Riesgo Hemorrágico de la Terapia Triple No lo Atenúa la Warfarina Bien Controlada

Bleeding Risk of Triple Therapy Not Attenuated by Well-Controlled Warfarin

In Older ACS Patients, Half-Dose Prasugrel as Safe as Clopidogrel But No More Effective

En Pacientes Ancianos, Media Dosis de Prasugrel es igual de Segura que el Clopidogrel aunque No Más Eficaz

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content